Eli Lilly announced Monday its obesity pill Foundayo significantly reduced sleep apnea severity in late-stage trials, setting up a potential FDA approval that could help 80 million Americans struggling with interrupted breathing during sleep. The drugmaker plans to file for federal approval by year’s end, expanding treatment options beyond cumbersome breathing machines most patients currently rely on.
Trial Results Show Major Reduction in Breathing Disorders
The pharmaceutical company tested Foundayo in two independent studies involving adults with moderate-to-severe obstructive sleep apnea who were also overweight or obese. Obstructive sleep apnea occurs when airways narrow or block during sleep, causing dangerous drops in oxygen levels and spikes in blood pressure that lead to serious complications including hypertension, heart failure, and stroke. The condition affects nearly one billion adults worldwide, yet most cases remain undiagnosed, according to Lilly’s findings.
Dr. Thomas Seck, senior vice president of product development at Lilly Cardiometabolic Health, emphasized the potential impact. Foundayo already rolled out across America in April 2026 for obesity treatment, and these new results position it as another weapon against sleep-related breathing disorders. The daily pill joins Lilly’s blockbuster injection Zepbound, which became the first medication approved for sleep apnea in December 2024.
Limited Options Drive Demand for New Treatments
Americans with sleep apnea face few alternatives beyond medications like Zepbound or positive airway pressure machines that force air through blocked passages during sleep. The National Council on Aging reports 80 million U.S. adults ages 20 and older suffer from the condition, creating massive demand for more convenient treatment options. The approval would mark another victory for GLP-1 treatments, a class of drugs originally developed for diabetes that have proven effective for weight loss and related health conditions.
What This Means
If the FDA approves Foundayo for sleep apnea by early 2027, millions of Americans could access a simple daily pill instead of relying on bulky breathing equipment or injectable medications. The move reflects how obesity drugs are expanding beyond weight loss into treating serious medical conditions tied to excess weight. For families dealing with sleep apnea’s dangers—including increased risks of heart attack and stroke—this development offers hope for safer, more effective treatment without invasive devices disrupting sleep and daily routines.
